Enobosarm, a selective androgen receptor modulator (SARM), increases lean bodymass (LBM) in advanced nsclc patients; updated results of two pivotal, international phase 3 trials - Crawford, J C; Johnston, M A; Hancock, M L (Support care cancer, 2014)
et al.